Status:
RECRUITING
Follow-up of Patients With Uveal Melanoma Adapted to the Risk of Relapse (SALOME)
Lead Sponsor:
Institut Curie
Conditions:
Uveal Melanoma
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Biomarkers search for early diagnosis of liver metastases in patients with uveal melanoma who benefit from a follow-up tailored to their personalized risk of relapse.
Detailed Description
High risk patients are referred for the medical oncology consultation to organize oncological surveillance after general staging of the disease. Signature of the informed consent of SALOME study, incl...
Eligibility Criteria
Inclusion
- Patient aged of 18 years or more.
- Patient with uveal melanoma with high metastatic relapse risk defined as :
- T2b/c/d ou ≥ T3,
- or chromosom 3 or chromosom 8 abnormality by CGH array.
- Completion of treatment of the primary tumor ≤ 2 months.
- Patient able to comply with the schedule of visits and blood samples of the study.
- Signed informed consent form or legal representative.
Exclusion
- Patient without french social insurance.
- Any social, medical or psychological condition making the research process impossible.
Key Trial Info
Start Date :
July 8 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 7 2037
Estimated Enrollment :
700 Patients enrolled
Trial Details
Trial ID
NCT04424719
Start Date
July 8 2020
End Date
July 7 2037
Last Update
September 3 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Institut Curie
Paris, France, 75005